- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02116842
Minimum Effective Dose (MED) & Epidural Bupivacaine
Comparison of the ED95 Dose of 0.075% and 0.1% Bupivacaine for Labour Analgesia in Primigravida.
Local anaesthetics are highly toxic drugs. They can cause toxicity by an absolute overdose, accidental injection in a blood vessel or slow absorption from the area of injection. The risk of toxicity when performing regional anaesthesia can be reduced significantly by injecting the optimal dose of local anaesthetic at the correct site.
To date most of the local anaesthetic dose finding studies for epidural labour analgesia has focused on ED50 ( the dose effective in 50% of patients). The purpose of this research study is to find out the ED95 dose (the dose effective in 95% of patients) of local anaesthetic for epidural analgesia in labour.
The dose determined from this research trial will guide the anaesthetists to the optimal starting dose of the local anaesthetics for epidural analgesia in labour. This would lead to decreased chances of toxicity and will improve patient safety.
We aim to recruit a total of 100 pregnant patients in early labour (cervical dilatation ≤ 5 cm) requesting epidural analgesia to answer the research question based on the continual reassessment method. Patients will be recruited according to well-defined criteria. They will be fully informed about the study and have the choice of not participating or opting out at any time during the study. It is not going to affect the kind of treatment they receive. The experts in the field with full safety precautions will perform this study at St James' Hospitals, Leeds.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Neville Young
- Phone Number: 44 113 392 6459
- Email: neville.young@leedsth.nhs.uk
Study Contact Backup
- Name: Leeds Sponsor Office Quality Assurance Department
- Phone Number: 44 113 392 2878
- Email: r&d@leedsth.nhs.uk
Study Locations
-
-
West Yorkshire
-
Leeds, West Yorkshire, United Kingdom, LS9 7TF
- Recruiting
- Leeds Teaching Hospitals NHS Trust
-
Principal Investigator:
- Dr Sandeep Varma
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- American Society of Anaesthesiologists (ASA) 1-3 patients
- Primigravida (1st pregnancy) patients requesting epidural analgesia in early labour (≤ 5 cm cervical dilatation.
Exclusion Criteria:
- Primigravida (1st pregnancy) patients requesting epidural analgesia in late labour (> 5 cm cervical dilatation)
- Multigravida patients ( ≥ 2nd pregnancy)
- ASA > 3
- Allergy to Bupivacaine
- Unable to give written informed consent
- BMI >35
- Abnormal blood coagulation profile
- Patients taking any medication that are indicated in the Summary of Product Characteristics (SPC) as not recommended
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 0.075% bupivacaine
Consenting patients randomised to receive 0.075% bupivacaine and 40 µg fentanyl.
|
Epidural block in early labour.
Given with different doses of bupivacaine in epidural block.
|
Experimental: 0.1% bupivacaine
Consenting patients randomised to receive 0.1% bupivacaine and 40 µg fentanyl.
|
Given with different doses of bupivacaine in epidural block.
Epidural block in early labour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effective dose in 95% of patients (ED95) dose of bupivacaine for a primigravida in early labour.
Time Frame: up to 30 minutes
|
To find out the ED95 dose of bupivacaine 0.075% and 0.1% for epidural analgesia for a primigravida in early labour .
|
up to 30 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Professor Philip M Hopkins, University of Leeds
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AN10/9307
- 11730 (Other Identifier: UKCRN)
- 2010-020020-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Turku University HospitalUniversity of TurkuCompleted
-
Centre Hospitalier René DubosCompletedDeciduitis; Complicating Pregnancy
Clinical Trials on 0.075% bupivacaine
-
Associazione Qol-oneRecruitingMyelodysplastic Syndromes | Anemia | Transfusion-dependent Anemia | Del(5Q)Italy
-
Revogenex, Inc.Suspended
-
AbbVieRecruitingMyelofibrosis (MF)United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Spain, Taiwan, Turkey, United... and more
-
AbbVieAvailableMyelofibrosis | Lymphoblastic Lymphoma | Acute Lymphocytic Leukemia (ALL)United States
-
Hospital Civil de GuadalajaraRecruitingEffect of Subarachnoid Hyperbaric Bupivacaine in Obese Pregnant Patients Undergoing Cesarean SectionAnesthesia | Obstetric Anesthesia ProblemsMexico
-
Integro TheranosticsRecruitingBreast Cancer | DCIS | Invasive Duct Carcinoma of BreastUnited States
-
Hospital Civil de GuadalajaraCompletedAnesthesia, ObstetricalMexico
-
DurectNycomedCompletedPostoperative PainAustria, Germany, Latvia, Poland, Sweden
-
DurectNycomedCompletedPostoperative PainFrance, Germany, Hungary, Latvia, Sweden, United Kingdom
-
Indiana UniversityCompletedPain, Postoperative | Acute Pain | ThoracicUnited States